- Clinical trials for ‘NG101’ show smooth progress from low-dose to medium-dose (Cohort 2)… 44-week results to be unveiled
- Selected to present in the gene therapy session alongside Eli Lilly, validating technological excellence
- Reyon Pharmaceutical to exclusively handle global production and supply of NG101 via its Chungju GMP facility
Elisigen, a gene therapy research and development company and a partner of REYON PHARM, announced that it will present the 44-week interim results of its Phase 1/2a clinical trial for the wet age-related macular degeneration (wAMD) gene therapy, ‘NG101,’ at the ‘44th American Society of Retina Specialists Annual Meeting (ASRS 2026),’ which will be held in Montreal, Canada, from the 15th to the 18th (local time).
ASRS is one of the most prestigious organizations for retina specialists and researchers worldwide. While numerous biotechs submit clinical abstracts to the conference, most are limited to poster presentations. In contrast, Elisigen has been selected for an oral presentation—a significant achievement that underscores the exceptional importance of its core clinical data.
Notably, the session to which Elisigen has been assigned is a forum dedicated to discussing the latest clinical outcomes in the field of next-generation therapeutics. It is particularly noteworthy that Elisigen was selected alongside global big pharma giant Eli Lilly as one of only two companies to present their gene therapy pipelines in this session. This signifies that the ASRS review committee considers the clinical data and technical value of NG101 a ‘Main Agenda’ item, confirming that Elisigen has been recognized for its world-class technological capabilities in the global gene therapy market.
This upcoming presentation follows the success of the low-dose (Cohort 1) data unveiled at the ‘ARVO (Association for Research in Vision and Ophthalmology)’ last May. At that time, the low-dose group demonstrated an overwhelming effect, with the number of additional injections required after NG101 administration reduced by approximately 89% (from an annual average of 9.8 to 1.1) over 52 weeks, and 83% of all subjects maintaining their vision with one or fewer injections. Given that major visual indicators were stably maintained without serious adverse reactions, this mid-dose (Cohort 2) presentation is expected to further solidify the clinical value of NG101 and its continuity as a next-generation treatment.
Based on a joint development agreement signed with Elisigen in 2020, REYON PHARM is responsible for the global production and supply of NG101. REYON PHARM has established a seamless production system for the successful commercialization and global market entry of NG101, utilizing its state-of-the-art GMP facility at its Chungju plant, which boasts world-class capabilities in gene therapy production.
A spokesperson for REYON PHARM stated, “Selection for an oral presentation at ASRS, the most authoritative global conference, signifies that NG101 has transcended the status of a ‘promising candidate’ and has secured its position as an innovative treatment standing shoulder-to-shoulder with global big pharma.” They added, “REYON PHARM will work closely with our partner and utilize our advanced production infrastructure to do our utmost to ensure that NG101 emerges as a blockbuster therapy leading the global market.”
Meanwhile, the presentation will be delivered by the principal investigator (PI), Dr. Peter Kertes, a professor in the Department of Ophthalmology and Vision Sciences at the University of Toronto, Canada. Dr. Kertes, a world-renowned authority in retinal, macular, and vitreous diseases, will provide a detailed explanation of the clinical value of NG101. The presentation is scheduled for July 16 at 9:15 PM (Korean Standard Time).
